Trends in the use of psychotropic drugs in people with intellectual disability in Taiwan: A nationwide outpatient service study, 1997-2007

Research in Developmental Disabilities

Volumn 35, Issue 2, 2014, Pages 364-372

  Hsu, Shang Wei ^a,b   Chiang, Po Huang ^a,b   Chang, Yu Chia ^a   Lin, Jin Ding ^c   Tung, Ho Jui ^a   Chen, Chao Yun ^a  

^a ASIA UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Intellectual disability; Psychotropic drugs

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; OFF LABEL DRUG USE; OUTPATIENT CARE; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; SEX DIFFERENCE; SOCIAL WELFARE; TAIWAN; TREND STUDY; URBAN AREA;

INTELLECTUAL DISABILITY; PSYCHOTROPIC DRUGS;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INTELLECTUAL DISABILITY; MALE; MENTAL DISORDERS; MIDDLE AGED; OFF-LABEL USE; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; TAIWAN; YOUNG ADULT;

EID: 84890393777     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2013.11.011     Document Type: Article

References (44)

1. Alonso J., Angermeyer M.C., Bernert S., Bruffaerts R., Brugha T.S., et al. Psychotropic drug utilization in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavia 2004, 109:55-64.
2. Australian Institute of Health and Welfare (2008). Disability in Australia: Intellectual Disability. (Bulletin 67). (accessed 07.07.13). http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx%3Fid=6442452891.
3. Beck C.A., Patten S.B., Williams J.V.A., Wang J.L., Currie S.R., et al. Antidepressant utilization in Canada. Social Psychiatry and Psychiatric Epidemiology 2005, 40:799-807.
4. Bureau of National Health Insurance National health insurance in Taiwan 2013, (accessed 02.15.13). http://www.nhi.gov.tw/English/webdata/webdata.aspx%3Fmenu=11%26menu_id=290%26webdata_id=2974%26WD_ID=290.
5. Bhaumik S., Tyrer F.C., McGrother C., Ganghadaran S.K. Psychiatric service use and psychiatric disorders in adults with intellectual disability. Journal of Intellectual Disability Research 2008, 52:986-995.
6. Bregman J.D. Current developments in the understanding of mental retardation part II: Psychopathology. Journal of the American Academy of Child & Adolescent Psychiatry 1991, 30:861-872.
7. Chiang P.H., Chang Y.C., Lin J.D., Tung H.J., Lin L.P., Hsu S.W. Healthcare utilization and expenditure analysis between individuals with intellectual disabilities and the general population in Taiwan: A population-based nationwide child and adolescent study. Research in Developmental Disabilities 2013, 34:2485-2492.
8. Chien I.C., Bih S.H., Chou Y.J., Lin C.H., Lee W.G., Chou P. Trends in the use of psychotropic drugs in Taiwan: A population-based National Health Insurance study, 1997-2004. Psychiatric Services 2007, 58:554-557.
9. Chu C.H., Lee Y.C., Huang Y.T., Yeh L.L., Huang K.H. The impact of hospitals' center of excellence initiative on prescribing pattern of antipsychotics in outpatient schizophrenia patients. Journal of Healthcare Management 2007, 8:301-316.
10. De Kuijper G., Hoekstra P., Visser F., Scholte F.A., Penning C., et al. Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription. Journal of Intellectual Disability Research 2010, 54:659-667.
11. Doan T.N., Lennox N.G., Taylor-Gomez M., Ware R.S. Medication use among Australian adults with intellectual disability in primary healthcare settings: A cross-sectional study. Journal of Intellectual and Developmental Disability 2013, 38:177-181.
12. Fletcher R., Loschen E., Stavrakaki C., First M. Diagnostic manual intellectual disability: A textbook of diagnosis of mental disorders in people with intellectual disability: DM-ID 2007, NADD Press, New York.
13. Ghaziuddin M. Autism in mental retardation. Current Opinion in Psychiatry 2000, 13:481-484.
14. Gillberg C., Soderstrom H. Learning disability. The Lancet 2003, 362:811-821.
15. Holden B., Gitlesen J.P. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Research in Developmental Disabilities 2004, 25:509-521.
16. Holland A.J. Psychiatry and mental retardation. International Review of Psychiatry 1999, 11:76-82.
17. La Malfa G., Lassi S., Bertelli M., Castellani A. Reviewing the use of antipsychotic drugs in people with intellectual disability. Human Psychopharmacology 2006, 21:73-89.
18. Leunissen C.L.F., de la Parra N.M., Tan I.Y., Rentmeester Th.W., Vader C.I., Veendrick-Meekes M.J.B.M., et al. Antiepileptic drugs with mood stabilizing properties and their relation with psychotropic drug use in institutionalized epilepsy patients with intellectual disability. Research in Developmental Disabilities 2011, 32:2660-2668.
19. Liao S.C., Chen W.J., Lee M.B., Lung F.W., Lai T.J., et al. Low prevalence of major depressive disorder in Taiwanese adults: Possible explanations and implications. Psychological Medicine 2012, 42:1227-1237.
20. Lin J.D., Lin P.Y., Chen L.M., Fang W.H., Lin L.P., Loh C.H. Serum glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) levels in children and adolescents with intellectual disabilities. Research in Developmental Disabilities 2010, 31:172-177.
21. Lin J.D., Lin P.Y., Lin L.P., Chang Y.Y., Wu S.R., Wu J.L. Physical activity and its determinants among adolescents with intellectual disabilities. Research in Developmental Disabilities 2010, 31:263-269.
22. Lin J.D., Lin P.Y., Lin L.P., Hsu S.W., Yen C.F., Fang W.H., et al. Serum uric acid, hyperuricemia and body mass index in children and adolescents with intellectual disabilities. Research in Developmental Disabilities 2009, 30:1481-1489.
23. Lin J.D., Loh C.H., Choi I.C., Yen C.F., Hsu S.W., Wu J.L., et al. High outpatient visits among people with intellectual disabilities caring in a disability institution in Taipei: A 4-year survey. Research in Developmental Disabilities 2007, 28:84-93.
24. Lin J.D., Yen C.F., Li C.W., Wu J.L. Health, healthcare utilization and psychiatric disorder in people with intellectual disability in Taiwan. Journal of Intellectual Disability Research 2005, 49:86-94.
25. Mamdani M., Rapoport M., Shulman K.I., Hermann N., Rochon P.A. Mental health-related drug utilization among older adults prevalence trends and costs. American Journal of Geriatric Psychiatry 2005, 13:892-900.
26. Matson J.L., Boisjoli J.A. Multiple versus single maintaining factors of challenging behaviors as assessed by the QABF for adults with intellectual disabilities. Journal of Intellectual and Developmental Disability 2007, 32:39-44.
27. Matson J.L., Gonzalez M.L., Terlonge C., Thorson R.T., Laud R.B. What symptoms predict the diagnosis of mania in persons with severe/profound intellectual disability in clinical practice?. Journal of Intellectual Disability Research 2007, 51:25-31.
28. Matson J.L., Mahan S. Antipsychotic drug side effects for persons with intellectual disability. Research in Developmental Disabilities 2010, 31:1570-1576.
29. Matson J.L., Terlonge C., Gonzalez M.L., Rivet T. An evaluation of social and adaptive skills in adults with bipolar disorder and severe/profound intellectual disability. Research in Developmental Disabilities 2006, 27:681-687.
30. National Health Research Institutes Data files 2011, http://nhird.nhri.org.tw/en/Data_Files.html (accessed 12.15.11).
31. National Health Research Institutes Data protection 2011, http://nhird.nhri.org.tw/en/Data_Protection.html (accessed 12.15.11).
32. Olfson M., Marcus S.C., Druss B., Elinson L., Tanielian T., et al. National trends in the outpatient treatment of depression. JAMA 2002, 287:203-209.
33. Paulose-Ram R., Jonas B.S., Orwig D., Safran M.A. Prescription psychotropic medication use among the U.S. adult population: results from the third National Health, Nutrition Examination Survey, 1988-1994. Journal of Clinical Epidemiology 2007, 57:309-317.
34. Pyles D.A.M., Muniz K., Cade A., Silva R. A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Research in Developmental Disabilities 1997, 18:185-214.
35. Rai D., Zitko P., Jones K., Lynch J., Araya R. Country- and individual-level socioeconomic determinants of depression: Multilevel cross-national comparison. British Journal of Psychiatry 2013, 202:195-203.
36. Ravera S., Visser S.t., Gier J.j., Berg L.T.W.J. Prevalence, cumulative incidence, monotherapy and combination therapy, and treatment duration of frequently prescribed psychoactive medications in the netherlands: Retrospective database analysis for the years 2000 to 2005. Clinical Therapeutics 2010, 32:2457-2466.
37. Richter T., Mann E., Meyer G., Haastert B., Kopke S. Prevalence of psychotropic medication use among german and austrian nursing home residents: A Comparison of 3 Cohorts. Journal of American Medical Directors Association 2012, 13:187.e7-187.e13.
38. Rodrigues M.A.P., Facchini L.A., Lima M.S. Modifications in psychotropic drug use patterns in a Southern Brazilian city. Revista de Saúde Pública 2006, 40:107-114.
39. Rose E., Bramham J., Young S., Paliokostas E., Xenitidis K. Neuropsychological characteristics of adults with comorbid ADHD and borderline/mild intellectual disability. Research in Developmental Disabilities 2009, 30:496-502.
40. Tonge B.J., Einfeld S.L., Krupinski J., Mackenzie A., McLaughlin M., et al. The use of factor analysis for ascertaining patterns of psychopathology in children with intellectual disability. Journal of Intellectual Disability Research 1996, 40:198-207.
41. Tsiouris J.A., Kim S.Y., Brown W.T., Pettinger J., Cohen J.I.L. Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large scale study. Journal of Autism and Developmental Disorders 2013, 43:719-731.
42. Warren C.R., Serrato J.J., Maguire G.A. Off-label uses of second-generation antipsychotic drugs. Taiwanese Journal of Psychiatry 2012, 26:162-176.
43. Weiss E., Hummer M., Koller D., Ulmer H., Fleischhacker W.W. Off-label use of antipsychotic drugs. Journal of Clinical Psychopharmacology 2000, 20:695-698.
44. World Health Organization Anatomical therapeutical chemical (ATC) classification index including defined daily doses (DDDs) for plain substances 2005, World Health Organization Collaborating Centre for Drug Statistics Methodology, Oslo.